Physician profile
Daniel Mark Ibach
NPI 1619947876
$36,202.84
in general payments reported to CMS, 2019-2025
84 companies · $4,474 in 2025
The $4,474 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,879 · 2020: $7,256 · 2021: $7,033 · 2022: $4,032 · 2023: $4,862 · 2024: $4,668 · 2025: $4,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,786.82 |
| Education | $216.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $6,773.97 | 2020-2025 | Monoferric, Cosela |
| E.R. Squibb & Sons, L.L.C. | $2,404.92 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Astrazeneca Pharmaceuticals LP | $1,863.54 | 2019-2025 | Enhertu, Tagrisso, Calquence |
| Merck Sharp & Dohme LLC | $1,517.60 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $1,513.69 | 2019-2023 | Kyprolis, Nplate, Xgeva |
| Janssen Biotech, INC. | $1,487.13 | 2019-2025 | Tecvayli, Erleada, Darzalex |
| Genentech USA, INC. | $1,448.33 | 2019-2025 | Phesgo, Perjeta, Itovebi |
| Genzyme Corporation | $1,331.49 | 2019-2025 | |
| Celgene Corporation | $1,179.23 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Novartis Pharmaceuticals Corporation | $1,169.92 | 2019-2025 | |
| Pfizer INC. | $1,140.02 | 2019-2025 | |
| Seagen INC. | $1,116.34 | 2019-2023 | Tukysa, Padcev, Adcetris |
| Glaxosmithkline, LLC. | $981.17 | 2020-2025 | Jemperli, Ojjaara, Blenrep |
| Regeneron Healthcare Solutions, INC. | $855.20 | 2019-2025 | Libtayo, Lynozyfic |
| Incyte Corporation | $798.65 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
Show all 84 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $734.27 | 2019-2025 | Trodelvy |
| Eisai INC. | $729.97 | 2019-2025 | |
| Abbvie INC. | $699.04 | 2020-2025 | |
| Karyopharm Therapeutics INC. | $608.27 | 2020-2025 | Xpovio |
| Alexion Pharmaceuticals, INC. | $531.83 | 2019-2025 | Ultomiris |
| Daiichi Sankyo INC. | $515.84 | 2019-2025 | Enhertu, Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $491.90 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $462.69 | 2019-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Astellas Pharma US INC | $438.95 | 2019-2025 | Padcev, Vyloy, Xtandi |
| Lilly USA, LLC | $416.84 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Exelixis INC. | $343.27 | 2019-2024 | Cabometyx |
| Puma Biotechnology, INC. | $264.79 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $258.49 | 2021-2023 | Imbruvica, Epkinly |
| Kite Pharma, INC. | $250.29 | 2020-2025 | Yescarta |
| Array Biopharma INC | $243.97 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Beigene USA, INC. | $202.17 | 2020-2025 | Brukinsa, Tevimbra |
| Epizyme, INC. | $198.89 | 2020-2021 | |
| Genmab U.S., INC. | $164.47 | 2023-2025 | Epkinly |
| Jazz Pharmaceuticals INC. | $162.31 | 2020-2025 | |
| Deciphera Pharmaceuticals INC. | $149.72 | 2021-2025 | Qinlock, Romvimza |
| Emd Serono, INC. | $132.47 | 2020-2025 | Bavencio |
| Acceleron Pharma, INC. | $130.08 | 2020-2021 | |
| Tersera Therapeutics LLC | $129.14 | 2019-2024 | Zoladex, Xermelo |
| Immunomedics, INC. | $124.74 | 2020 | |
| Sobi, INC | $115.22 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.55 | 2019-2025 | Gilotrif |
| Adc Therapeutics America, INC. | $111.59 | 2022-2025 | |
| Aveo Pharmaceuticals, INC. | $98.29 | 2022-2025 | Fotivda |
| Mirati Therapeutics, INC. | $89.23 | 2023 | Krazati |
| Rigel Pharmaceuticals, INC. | $86.83 | 2021-2023 | Tavalisse, Rezlidhia |
| Taiho Oncology, INC. | $85.23 | 2020-2025 | |
| Novocure INC. | $83.11 | 2024-2025 | Optune Lua (Novottf-200t) |
| Morphosys, US INC. | $81.94 | 2021-2024 | Monjuvi |
| Secura Bio, INC. | $81.35 | 2020-2022 | |
| Blueprint Medicines Corporation | $75.71 | 2023-2024 | Ayvakit |
| Ipsen Biopharmaceuticals, INC | $71.46 | 2019-2024 | Onivyde |
| Myriad Genetic Laboratories, INC. | $71.19 | 2021-2023 | Precisetumor, Myrisk |
| Beone Medicines USA, INC. | $70.09 | 2025 | Tevimbra, Brukinsa |
| Kyowa Kirin, INC. | $65.88 | 2019-2023 | Poteligeo |
| G1 Therapeutics, INC. | $63.84 | 2022-2023 | Cosela |
| Heron Therapeutics, INC. | $60.66 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $57.26 | 2019-2024 | Tecvayli, Talvey, Darzalex |
| Intuitive Surgical, INC. | $51.55 | 2022 | |
| Springworks Therapeutics, INC. | $50.23 | 2024-2025 | Ogsiveo |
| Agios Pharmaceuticals, INC. | $45.03 | 2019-2022 | |
| Myovant Sciences INC. | $43.42 | 2021-2022 | |
| Stemline Therapeutics INC. | $42.37 | 2021-2023 | Orserdu |
| Foundation Medicine, INC. | $42.32 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $42.29 | 2020 | |
| Servier Pharmaceuticals LLC | $40.32 | 2022-2024 | |
| Coherus Oncology, INC. | $37.84 | 2020-2021 | |
| Syndax Pharmaceuticals, INC. | $26.62 | 2025 | |
| Tg Therapeutics, INC. | $25.33 | 2021 | |
| Clovis Oncology, INC. | $25.30 | 2019-2020 | |
| Geron Corporation | $24.86 | 2025 | Rytelo |
| Macrogenics, INC. | $24.56 | 2022 | |
| Pharmaessentia USA Corporation | $24.36 | 2023 | Besremi |
| Alnylam Pharmaceuticals INC. | $22.16 | 2020 | |
| Verastem, INC. | $20.54 | 2020 | |
| Janssen Pharmaceuticals, INC | $19.73 | 2019-2020 | |
| Tesaro, INC. | $19.71 | 2019 | |
| Apellis Pharmaceuticals, INC. | $19.51 | 2023 | Empaveli |
| Verity Pharmaceuticals INC. | $19.07 | 2023 | Trelstar |
| Sun Pharmaceutical Industries INC. | $18.47 | 2025 | |
| Sanofi-Aventis U.S. LLC | $15.83 | 2021 | |
| Dova Pharmaceuticals | $15.35 | 2020 | |
| Mylan Institutional INC. | $13.60 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $13.02 | 2020 | |
| Advanced Accelerator Applications | $11.42 | 2019 |
Drugs and devices associated with these payments
Opdivo $698Keytruda $679Imbruvica $553Libtayo $425Enhertu $391Kisqali $385Tukysa $376Tecvayli $357Adcetris $356Trodelvy $344Padcev $337Lenvima $333Epkinly $315Xpovio $304Ultomiris $300Elrexfio $279Erleada $267Sarclisa $247Jakafi $238Verzenio $238Jaypirca $238Jemperli $234Darzalex $227Monjuvi $217Reblozyl $217Braftovi $213Mektovi $213Lorbrena $207Ninlaro $201Xtandi $197Nubeqa $183Venclexta $177Phesgo $160Perjeta $160Ibrance $160Lynozyfic $155Tagrisso $142Itovebi $141Retevmo $137Zynyz $136Calquence $136Xofigo $135Cabometyx $134Pomalyst $133Akeega $132Ojjaara $130Stivarga $125Xalkori $121Talzenna $120Brukinsa $119Balversa $117Scemblix $116Talvey $115Zepzelca $115Fabhalta $106Tecentriq $105Tevimbra $104Rybrevant $103Ayvakit $94.69Lynparza $93.44Orgovyx $93.07Promacta $91.97Bosulif $90.84Eliquis $90.45Krazati $89.23Inlyta $88.21Qinlock $87.72Pluvicto $85.28Optune Lua (Novottf-200t) $83.11Vitrakvi $82.55Bavencio $80.10Enjaymo $73.74Opdualag $68.41Gilotrif $62.99Vonjo $58.87Jevtana $58.78Imfinzi $58.44Inqovi $57.07Lonsurf $57.07Yescarta $55.08Polivy $54.09Paxlovid $51.23Fotivda $50.63Ogsiveo $50.23Pemazyre $48.26Kadcyla $48.16Cosela $44.85Alecensa $43.30Vyloy $43.10Carvykti $38.67Precisetumor $38.55Lutathera $38.52Fruzaqla $37.40Monoferric $36.94Onivyde $34.84Nerlynx $34.19Wayrilz $33.80Kyprolis $33.60Xospata $31.85Xgeva $29.66
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ibach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.